



201 Technology Drive • Irvine • California • 92618
Telephone: (949) 450-5400
Facsimile: (949) 450-5300
Email: IR@endocare.com
Website: www.endocare.com

FOR RELEASE on August 7, 2008 at 6:00 am (EDT)

Investor Contact:
Matt Clawson
Allen & Caron, Inc.
(949) 474-4300
matt@allencaron.com
www.allencaron.com

Media Contact:
Len Hall
Allen & Caron, Inc.
(949) 474-4300
len@allencaron.com
www.allencaron.com

For Additional Information:
Craig T. Davenport, CEO
Michael R. Rodriguez, CFO
Endocare, Inc.
(949) 450-5400
www.endocare.com

ENDOCARE COMMENTS ON UNSOLICITED PROPOSAL

IRVINE, Calif. (August 7, 2008) . . . The Board of Directors of Endocare, Inc. (NASDAQ:ENDO) received on August 6, 2008 an unsolicited proposal from HealthTronics, Inc. (NASDAQ: HTRN) to purchase all of the outstanding shares of Endocare common stock for \$2.28 per share in cash.

Endocare's Board of Directors, consistent with its fiduciary duties, and in consultation with its financial and legal advisors, will review and consider HealthTronics' unsolicited proposal carefully and promptly in the context of Endocare's strategic plans and pursue the best course of action for the long-term value to stockholders.

About Endocare

Endocare, Inc.—www.endocare.com— is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

###